MODKIFY

CSL Behring GmbH

Trademark Registered: 2021-08-31

Trademark Application Details

Status

630

Live/Pending

NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER

Research	OneLook Acronym Finder
Serial Number	79294183
Registration Number	6465740
Mark Drawing Code	4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form

Timeline

2020-07-24	Application Filed
2020-09-24	Location: INITIAL REVIEW/SERIALIZATION BRANCH(MAILROOM)
2020-09-24	Status: Live/Pending
2020-09-28	Transaction Date
2021-08-31	Trademark Registered

Trademark Applicants & Owners

Owner:	CSL Behring GmbH
Address	Emil-von-Behring Str. 76 35041 Marburg DE
Legal Entity Type	Limited Liability Company
Legal Entity State	DE

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

Frank Sch?ne de la Nuez
Emil-von-Behring-Strasse 76
35041 Marburg
FED REP GERMANY

Good, Services, and Codes

International Codes:	5
U.S. Codes:	006,018,044,046,051,052

Type Code	Type
GS0051	Pharmaceutical preparations; antibodies; blood products; blood plasma; blood plasma fractions; blood plasma products for medical purposes; recombinant proteins for medical purposes; cell cultures for medical purposes
GS0051	Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza

Type Code

Type

GS0051

Pharmaceutical preparations; antibodies; blood products; blood plasma; blood plasma fractions; blood plasma products for medical purposes; recombinant proteins for medical purposes; cell cultures for medical purposes

GS0051

Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza

Trademark Filing History

Description	Date	Event Coding
SN ASSIGNED FOR SECT 66A APPL FROM IB	2020-09-24	1 REPR M:
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	2020-09-28	2 NWOS I:Incoming Correspondence
APPLICATION FILING RECEIPT MAILED	2020-10-02	3 MAFR O:Outgoing Correspondence
ASSIGNED TO EXAMINER	2020-11-11	4 DOCK D:Assigned to Examiner
NON-FINAL ACTION WRITTEN	2020-11-16	5 CNRT R:Renewal
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW	2020-11-17	6 RFCR E:E-Mail
REFUSAL PROCESSED BY MPU	2020-12-03	7 RFRR P:
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB	2020-12-03	8 RFCS P:
REFUSAL PROCESSED BY IB	2020-12-20	9 RFNT P:
TEAS RESPONSE TO OFFICE ACTION RECEIVED	2021-05-11	10 TROA I:Incoming Correspondence
CORRESPONDENCE RECEIVED IN LAW OFFICE	2021-05-11	11 CRFA I:Incoming Correspondence
TEAS/EMAIL CORRESPONDENCE ENTERED	2021-05-11	12 TEME I:Incoming Correspondence
APPROVED FOR PUB - PRINCIPAL REGISTER	2021-05-12	13 CNSA O:Outgoing Correspondence
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	2021-05-26	14 NONP E:E-Mail
PUBLISHED FOR OPPOSITION	2021-06-15	15 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	2021-06-15	16 NPUB E:E-Mail
REGISTERED-PRINCIPAL REGISTER	2021-08-31	17 R.PR A:Allowance for Publication
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB	2021-11-30	18 FICR P:
FINAL DISPOSITION PROCESSED	2022-02-10	19 FIMP P:
FINAL DISPOSITION NOTICE SENT TO IB	2022-02-10	20 FICS P:
FINAL DECISION TRANSACTION PROCESSED BY IB	2022-03-07	21 FINO P:
NEW REPRESENTATIVE AT IB RECEIVED	2022-11-04	22 NREP P:

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.